KRAS and neoplasm: For example, the parameters of our fitted model have interesting interpretations: of the five genes highlighted in Fig. 2a as having the highest mutation rates relative to the BMR, two (TP53, CDKN2A) are known tumour suppressors49,50 and KRAS is an oncogene51.